HL 036

Drug Profile

HL 036

Alternative Names: Anti-TNF-alpha protein - HanAll Biopharma; HL036; TNF-alpha blocker - HanAll Biopharma

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HanAll Biopharma
  • Developer HanAll Biopharma; Unknown
  • Class Biobetters; Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes
  • Research Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 05 Nov 2017 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT03334539)
  • 12 Sep 2017 HanAll BioPharma plans to initiate a phase II trial for Dry eyes in the US (Ophthalmic) (NCT03334539) by the end of November 2017
  • 12 Sep 2017 HL-036 licensed to Harbour BioMed in Greater China, including Hong Kong, Macau and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top